Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Lung Cancer. 2018 May 22;122:67–71. doi: 10.1016/j.lungcan.2018.05.020

Table 3.

Overall Survival (OS) By Genotype

Molecular Driver 5-Year OS
(%)		 ALK vs. EGFR
P-value		 ALK vs. KRAS
P-Value
Stage I & II Patients
ALK 84 0.383 0.472
EGFR* 87
KRAS 72
Stage III Patients
ALK 29 0.545 0.844
EGFR* 39
KRAS 38
*

Patients who received EGFR tyrosine kinase inhibitors are excluded